Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07047677
Recruiting Observational

Ex Vivo Evaluation on Human Tissue of the Binding of Experimental Radiolabeled Ligands

NCT07047677 · tracked via the Priya Life Science France tracker
Sponsor
Central Hospital, Nancy, France
Phase
Observational
Started
2025-11-01
Last updated
2026-06-04

Condition(s) studied

Tissue Model

Investigational drug(s) / intervention(s)

Early assessment of tissue uptake of experimental ligands

Early assessment of tissue uptake of experimental ligands: Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue using autohistoradiography

Study summary

The HERO project aims to structure an ex vivo screening platform, based on anonymized human tissues, to early assess the tissue fixation of experimental ligands in an ethical, translational approach that complies with the principles of the 3Rs (Replacement, Reduction, Refinement).

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Patients who underwent surgical resection at the Nancy University Hospital after 2019 (Information provided in the welcome booklet or on posters displayed in waiting rooms, mentioning the possible use of data or resection specimens, unless otherwise stated). * No documented objection, in accordance with the MR004 methodology. * Frozen human tissues (slides, blocks, or sections) from surgical resection or biopsy, transmitted by the CRB or the biopathology department. * Samples are fully anonymized before being made available for analysis. Exclusion Criteria: * • Unusable tissue (degraded, insufficient, contaminated, poorly preserved). * Lack of traceability of the material. * Explicit opposition from the patient to the use of their tissue for research.

Primary outcome measure(s)

  • Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue by autohistoradiography — 10 days
    Signal /background noise ration, in region of interest

Trial sites (1)

FacilityCityRegionStatus
Chru Nancy Vandœuvre-lès-Nancy France Recruiting

More Central Hospital, Nancy, France trials in France

Implementation of Mobile Intensive Care Unit Ultrasound Based Management for Acute Dyspnea Starting soon
ADvanced ALzheimer Disease and Effects of Protologic and LAnguage Rehabilitation Tools in Nursing Home (ADALPA) Starting soon
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy Active, not recruiting
Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II Recruiting
A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047677 on ClinicalTrials.gov ↗ ← All trials in France